Incidence of chemotherapy-induced neutropenia in HIV-infected and uninfected patients with breast cancer receiving neoadjuvant chemotherapy.

S Afr Med J

Department of Radiation Oncology, School of Clinical Medicine, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

Published: June 2017

AI Article Synopsis

  • Chemotherapy-induced neutropenia (CIN) can lead to serious treatment complications, particularly in patients with HIV. The study aimed to compare the incidence of CIN in HIV-infected versus uninfected patients undergoing chemotherapy for breast cancer.
  • A review of medical records from 65 women revealed that HIV-infected patients, who were generally younger and more advanced in disease stage, had a significantly higher risk of developing CIN—almost double that of their uninfected counterparts.
  • The findings highlighted that HIV is a critical risk factor for CIN in chemotherapy patients, suggesting the need for careful monitoring and management in these individuals to improve treatment outcomes.

Article Abstract

Background: Chemotherapy-induced neutropenia (CIN) can result in poor tolerance of chemotherapy, leading to dose reductions, delays in therapy schedules, morbidity and mortality. Actively identifying predisposing risk factors before treatment is of paramount importance. We hypothesised that chemotherapy is associated with a greater increase in CIN and its complications in HIV-infected patients than in those who are not infected.

Objective: To establish the incidence of CIN in HIV-infected and uninfected patients undergoing chemotherapy.

Methods: A retrospective chart review and analysis was conducted in the oncology departments at Inkosi Albert Luthuli Central Hospital and Addington Hospital, Durban, South Africa. The study population consisted of 65 previously untreated women of all ages with stage II - IV breast cancer and known HIV status treated with neoadjuvant chemotherapy from January 2012 to December 2015.

Results: HIV-infected patients formed 32.3% of the group, and 95.2% of them were on antiretroviral therapy. The mean age (standard deviation (SD)) of the cohort was 48.5 (13.2) years (40.6 (9.6) years for the HIV-infected group v. 52.0 (13.1) years for the uninfected group; p<0.001). Ninety-five neutropenia episodes were observed (rate 0.85 per 1 year of follow-up time). Following multivariate adjustment, patients with HIV infection were almost two times more likely to develop CIN (hazard ratio (HR) 1.76, 95% confidence interval (CI) 1.06 - 2.92; p=0.029. A high baseline absolute neutrophil count (ANC) (HR 0.80, 95% CI 0.68 - 0.95; p=0.005) remained significantly associated with protection against CIN.

Conclusions: HIV-infected patients were younger than those who were not infected, and presented at a more locally advanced stage of disease. HIV infection was an independent predictor for CIN. HIV-infected patients had an almost two-fold increased risk of developing CIN and developed neutropenia at a much faster rate. A high baseline white cell count and ANC were protective against CIN.

Download full-text PDF

Source
http://dx.doi.org/10.7196/SAMJ.2017.v107i7.12309DOI Listing

Publication Analysis

Top Keywords

hiv-infected patients
16
chemotherapy-induced neutropenia
8
hiv-infected uninfected
8
uninfected patients
8
breast cancer
8
neoadjuvant chemotherapy
8
cin hiv-infected
8
hiv infection
8
high baseline
8
hiv-infected
7

Similar Publications

Cryptococcal meningitis is a major cause of death in HIV/AIDS patients due to the existence of in the central nervous system. Our objective was to evaluate the prevalence of Cryptococcus antigenuria in a population of HIV-infected patients in Libreville, Gabon. : This study was conducted from April to October 2021 at the Infectious Diseases ward of the Centre Hospitalier Universitaire de Libreville.

View Article and Find Full Text PDF

The value of metagenomic next-generation sequencing with blood samples for the diagnosis of disseminated tuberculosis.

Front Cell Infect Microbiol

December 2024

Department of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Objective: The aim of this study was to assess the clinical value of metagenomic next-generation sequencing (mNGS) of blood samples for the identification of disseminated tuberculosis (DTB).

Methods: A total of 48 individuals suspected of DTB were enrolled. All patients underwent mNGS of peripheral blood and conventional microbiological tests.

View Article and Find Full Text PDF

Objective: To evaluate the effectiveness of leukocyte, NLR, procalcitonin and C-reactive protein as the markers of acute peritonitis in patients with HIV-infection.

Material And Methods: The study included 83 HIV-infected patients with various diseases complicated by acute peritonitis. Leukocytes, procalcitonin and C-reactive protein, as well as immune status and viral load were determined in peripheral blood before surgery.

View Article and Find Full Text PDF

HIV-2 infection although less virulent compared to HIV-1 is endemic in many parts of West Africa. In Burkina Faso, few data exist on HIV-2 genotypic resistance. The objective of this study was to assess HIV-2 genotypic resistance and viral load in adult patients infected with HIV-2 in Burkina Faso.

View Article and Find Full Text PDF

Introduction: The full extent of interactions between human immunodeficiency virus (HIV) infection, injection drug use, and the human microbiome is unclear. In this study, we examined the microbiomes of HIV-positive and HIV-negative individuals, both drug-injecting and non-injecting, to identify bacterial community changes in response to HIV and drug use. We utilized a well-established cohort of people who inject drugs in Puerto Rico, a region with historically high levels of injection drug use and an HIV incidence rate disproportionately associated with drug use.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!